- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Hypoactive Sexual Desire Disorder (HSDD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Hypoactive Sexual Desire Disorder (HSDD) Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Hypoactive Sexual Desire Disorder (HSDD) Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Buspirone segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Hypoactive Sexual Desire Disorder (HSDD) Treatment include AMAG Pharmaceuticals, Allergan, Plc., Ivix LLX, EndoCeutics, Inc., and Emotional Brain BV, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Hypoactive Sexual Desire Disorder (HSDD) Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Buspirone
Bupropion
Testosterone
Flibanserin
Bremelanotide
Cognitive Behavior Therapy
Market segment by Application, can be divided into
Hospitals
Clinic
Others
Market segment by players, this report covers
AMAG Pharmaceuticals
Allergan, Plc.
Ivix LLX
EndoCeutics, Inc.
Emotional Brain BV
S1 Biopharma, Inc.
Sprout Pharmaceuticals, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Hypoactive Sexual Desire Disorder (HSDD) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Hypoactive Sexual Desire Disorder (HSDD) Treatment, with revenue, gross margin and global market share of Hypoactive Sexual Desire Disorder (HSDD) Treatment from 2019 to 2022.
Chapter 3, the Hypoactive Sexual Desire Disorder (HSDD) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Hypoactive Sexual Desire Disorder (HSDD) Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Hypoactive Sexual Desire Disorder (HSDD) Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Hypoactive Sexual Desire Disorder (HSDD) Treatment
1.2 Classification of Hypoactive Sexual Desire Disorder (HSDD) Treatment by Type
1.2.1 Overview: Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Type in 2021
1.2.3 Buspirone
1.2.4 Bupropion
1.2.5 Testosterone
1.2.6 Flibanserin
1.2.7 Bremelanotide
1.2.8 Cognitive Behavior Therapy
1.3 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Application
1.3.1 Overview: Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size & Forecast
1.5 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast by Region
1.5.1 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Region, (2017-2022)
1.5.3 North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Drivers
1.6.2 Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Restraints
1.6.3 Hypoactive Sexual Desire Disorder (HSDD) Treatment Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 AMAG Pharmaceuticals
2.1.1 AMAG Pharmaceuticals Details
2.1.2 AMAG Pharmaceuticals Major Business
2.1.3 AMAG Pharmaceuticals Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.1.4 AMAG Pharmaceuticals Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 AMAG Pharmaceuticals Recent Developments and Future Plans
2.2 Allergan, Plc.
2.2.1 Allergan, Plc. Details
2.2.2 Allergan, Plc. Major Business
2.2.3 Allergan, Plc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.2.4 Allergan, Plc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Allergan, Plc. Recent Developments and Future Plans
2.3 Ivix LLX
2.3.1 Ivix LLX Details
2.3.2 Ivix LLX Major Business
2.3.3 Ivix LLX Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.3.4 Ivix LLX Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Ivix LLX Recent Developments and Future Plans
2.4 EndoCeutics, Inc.
2.4.1 EndoCeutics, Inc. Details
2.4.2 EndoCeutics, Inc. Major Business
2.4.3 EndoCeutics, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.4.4 EndoCeutics, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 EndoCeutics, Inc. Recent Developments and Future Plans
2.5 Emotional Brain BV
2.5.1 Emotional Brain BV Details
2.5.2 Emotional Brain BV Major Business
2.5.3 Emotional Brain BV Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.5.4 Emotional Brain BV Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Emotional Brain BV Recent Developments and Future Plans
2.6 S1 Biopharma, Inc.
2.6.1 S1 Biopharma, Inc. Details
2.6.2 S1 Biopharma, Inc. Major Business
2.6.3 S1 Biopharma, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.6.4 S1 Biopharma, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 S1 Biopharma, Inc. Recent Developments and Future Plans
2.7 Sprout Pharmaceuticals, Inc.
2.7.1 Sprout Pharmaceuticals, Inc. Details
2.7.2 Sprout Pharmaceuticals, Inc. Major Business
2.7.3 Sprout Pharmaceuticals, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
2.7.4 Sprout Pharmaceuticals, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Sprout Pharmaceuticals, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Hypoactive Sexual Desire Disorder (HSDD) Treatment Players Market Share in 2021
3.2.2 Top 10 Hypoactive Sexual Desire Disorder (HSDD) Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Hypoactive Sexual Desire Disorder (HSDD) Treatment Players Head Office, Products and Services Provided
3.4 Hypoactive Sexual Desire Disorder (HSDD) Treatment Mergers & Acquisitions
3.5 Hypoactive Sexual Desire Disorder (HSDD) Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2028)
6.2 North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2028)
6.3 North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Country
6.3.1 North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2028)
6.3.2 United States Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2028)
7.2 Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2028)
7.3 Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Country
7.3.1 Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2028)
7.3.2 Germany Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
7.3.3 France Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Region
8.3.1 Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Region (2017-2028)
8.3.2 China Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8.3.5 India Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2028)
9.2 South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2028)
9.3 South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Country
9.3.1 South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size by Country
10.3.1 Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Region (2023-2028)
Table 6. AMAG Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. AMAG Pharmaceuticals Major Business
Table 8. AMAG Pharmaceuticals Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 9. AMAG Pharmaceuticals Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Allergan, Plc. Corporate Information, Head Office, and Major Competitors
Table 11. Allergan, Plc. Major Business
Table 12. Allergan, Plc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 13. Allergan, Plc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Ivix LLX Corporate Information, Head Office, and Major Competitors
Table 15. Ivix LLX Major Business
Table 16. Ivix LLX Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 17. Ivix LLX Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. EndoCeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. EndoCeutics, Inc. Major Business
Table 20. EndoCeutics, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 21. EndoCeutics, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Emotional Brain BV Corporate Information, Head Office, and Major Competitors
Table 23. Emotional Brain BV Major Business
Table 24. Emotional Brain BV Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 25. Emotional Brain BV Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. S1 Biopharma, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. S1 Biopharma, Inc. Major Business
Table 28. S1 Biopharma, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 29. S1 Biopharma, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Sprout Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Sprout Pharmaceuticals, Inc. Major Business
Table 32. Sprout Pharmaceuticals, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Product and Solutions
Table 33. Sprout Pharmaceuticals, Inc. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 35. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 36. Breakdown of Hypoactive Sexual Desire Disorder (HSDD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Hypoactive Sexual Desire Disorder (HSDD) Treatment Players Head Office, Products and Services Provided
Table 38. Hypoactive Sexual Desire Disorder (HSDD) Treatment Mergers & Acquisitions in the Past Five Years
Table 39. Hypoactive Sexual Desire Disorder (HSDD) Treatment New Entrants and Expansion Plans
Table 40. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) by Type (2017-2022)
Table 41. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Share by Type (2017-2022)
Table 42. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Forecast by Type (2023-2028)
Table 43. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022)
Table 44. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Forecast by Application (2023-2028)
Table 45. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 46. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 47. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 48. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 49. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 50. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 51. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 52. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 53. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 54. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 55. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 56. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 57. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 58. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 59. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 60. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 61. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Region (2017-2022) & (USD Million)
Table 62. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Region (2023-2028) & (USD Million)
Table 63. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 64. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 65. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 66. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 67. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 68. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 69. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 70. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 71. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 72. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 73. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 74. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Hypoactive Sexual Desire Disorder (HSDD) Treatment Picture
Figure 2. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Type in 2021
Figure 3. Buspirone
Figure 4. Bupropion
Figure 5. Testosterone
Figure 6. Flibanserin
Figure 7. Bremelanotide
Figure 8. Cognitive Behavior Therapy
Figure 9. Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Application in 2021
Figure 10. Hospitals Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Region (2017-2028)
Figure 16. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Region in 2021
Figure 17. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Drivers
Figure 23. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Restraints
Figure 24. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Trends
Figure 25. AMAG Pharmaceuticals Recent Developments and Future Plans
Figure 26. Allergan, Plc. Recent Developments and Future Plans
Figure 27. Ivix LLX Recent Developments and Future Plans
Figure 28. EndoCeutics, Inc. Recent Developments and Future Plans
Figure 29. Emotional Brain BV Recent Developments and Future Plans
Figure 30. S1 Biopharma, Inc. Recent Developments and Future Plans
Figure 31. Sprout Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 32. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Share by Players in 2021
Figure 33. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 34. Global Top 3 Players Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share in 2021
Figure 35. Global Top 10 Players Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share in 2021
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 37. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Share by Type in 2021
Figure 38. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Share Forecast by Type (2023-2028)
Figure 39. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Share by Application in 2021
Figure 40. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Share Forecast by Application (2023-2028)
Figure 41. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Type (2017-2028)
Figure 42. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Application (2017-2028)
Figure 43. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Country (2017-2028)
Figure 44. United States Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Type (2017-2028)
Figure 48. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Application (2017-2028)
Figure 49. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Country (2017-2028)
Figure 50. Germany Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Type (2017-2028)
Figure 56. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Region (2017-2028)
Figure 58. China Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. South Korea Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Type (2017-2028)
Figure 65. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Application (2017-2028)
Figure 66. South America Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East and Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Type (2017-2028)
Figure 70. Middle East and Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Sales Market Share by Application (2017-2028)
Figure 71. Middle East and Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue Market Share by Country (2017-2028)
Figure 72. Turkey Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. UAE Hypoactive Sexual Desire Disorder (HSDD) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
